Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isolagen Therapy is an autologous cell-based biologic therapy consisting of a patient's own dermal fibroblasts. Developed by Castle Creek Biosciences (following its acquisition of Fibrocell Science), the treatment involves harvesting a small skin biopsy from the patient, expanding the fibroblast cells in a laboratory setting, and re-injecting them into the patient's restrictive burn scar tissue. The therapy is designed to remodel the scar tissue and improve the range of motion in joint areas affected by stable restrictive burn scars. The manufacturing process utilizes a patented technology to create tailored cell-based doses for each patient. While it was evaluated in a Phase 2 pilot study, the clinical development for the restrictive burn scar indication was subsequently withdrawn.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Isolagen Therapy.